Firms modify their vaccine marketing agreement so that Connaught Labs will market directly all pediatric biologicals and vaccines and Squibb will continue to market Connaught's Fluzone influenza vaccine for adults and will have the option to market any other vaccines developed by Connaught for use in adults. Under a 1983 agreement, Squibb distributed some of Connaught's pediatric vaccines in the U.S. "The new arrangement allows Connaught to make further significant investments in its direct sales and distribution capabilities in the U.S. market," Connaught said.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.